Post by The Clinician eXchange

#Medtech Leaders: The recent CNN report on the link between phthalates and infant mortality is more than a headline: it is a regulatory inflection point for 2026. As the clinical evidence mounts, the "standard of care" in neonatal units is shifting toward phthalate-free environments. For manufacturers, this means your material science is now a core part of your value proposition. If you cannot provide a transparent chemical roadmap to a Value Analysis Committee, your market access in pediatrics is at risk. At The Clinician eXchange (TCX), we help you navigate this transition. We use our KOL Management and Value Analysis eXpertise to help you turn your safety-by-design efforts into a competitive advantage in the modern hospital ecosystem. Don't just meet the regulation. Lead the clinical standard. Schedule a call to learn more: https://lnkd.in/gdn7Ak5H Want more Medtech and healthcare insights? Sign up for our monthly newsletter 👉 https://lnkd.in/gNMsZR4e Original article: https://lnkd.in/giaJ_E6A #PediatricSafety #Medtech #MaterialScience #TCX #ValueAnalysis #NICU #HealthcareInnovation #2026Outlook